Retooling treatment in oligometastatic oesophageal cancer.

Competing Interests: MAH reports payments for teaching and support for meeting attendance from ESMO and ESTRO; participation in advisor boards for Pancreatic Cancer UK, AMMF, Cancer Trial Ireland; and a leadership role for RADNET City of London. ECS reports grants and personal fees from BMS and Astra Zeneca outside the submitted work; personal fees from Amgen, Daiichi Sankyo, Merck, Viracta, Astellas, Novartis, Pfizer, Zymeworks, and Beigene outside the submitted work; personal fees and non-financial support from Mirati outside the submitted work; is Chair of the EORTC Gastric Cancer Taskforce 2021–2024; and is has been a UK and Ireland Oesophagogastric Cancer Group trustee since 2022. AC reports no conflicts of Interest. ES is supported by the NIHR Biomedical Research Centre at Oxford. The views expressed in this Comment are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health. MAH is supported by funding from the NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust.